Renhe Pharmacy To Acquire Jiangxi Kangmei Healthcare And Jiangxi Yaodu Renhe Pharmaceutical
This article was originally published in PharmAsia News
Renhe Pharmacy will issue 60-90 million private shares, priced at least RMB 6.74 per share, to 10 or fewer potential buyers. The raised fund will be used to acquire the firm's controlling shareholder Renhe (Group) Development's 100 percent stake in both Jiangxi Kangmei Healthcare and Jiangxi Yaodu Renhe Pharmaceutical. Renhe Pharmacy expresses that the acquisition will reduce the number of related deals, thus strengthening its independence in purchase, production and sales. After the acquisition, the company will add 15 pharmaceutical formulations and nine food formulations as well as increase production capacity in health products and external sterilizing items. It will also introduce new organizational investors to further improve its legal and management structure. (Click here for more - Chinese Language)
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.